Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
General Drug Use-results Survey of Rituxan for Refractory Pemphigus Vulgaris and Pemphigus Foliaceus
jRCT2031220115Recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoints: Incidence of adverse events, Incidence of adverse drug reactions and 3 more. Started Jun 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on jRCT2031220115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220115.